Archimedic Appoints M. Alexander Shaw, PhD as Chief Executive Officer
September 12 2024 - 10:05AM
Business Wire
Archimedic, a medical device development firm that provides
technical, regulatory, and commercial services to its clients, has
appointed M. Alexander Shaw, PhD, as Chief Executive Officer. In
this role, Dr. Shaw will lead Archimedic in helping companies
transform novel technologies into market-ready products that
address technical, regulatory, usability, and commercial needs.
Dr. Shaw joins founder Eric Sugalski on Archimedic’s executive
team. Mr. Sugalski has led the company since its beginning, growing
it into a leader in medical device development services. “Dr.
Shaw’s medical product development expertise combined with his
experience in successfully leading and growing a life-science
consulting business makes him a perfect fit for helping Archimedic
achieve its next phase of growth,” said Mr. Sugalski.
Mr. Sugalski will assume the role of Chief Technology Officer.
In this role, Mr. Sugalski will leverage his extensive background
in engineering, regulatory affairs, and commercial strategy to help
clients advance their technologies into market-focused, derisked
solutions. “I am excited to be stepping into this hands-on role
working directly with our talented team and clients to advance new
medical technologies,” states Mr. Sugalski.
Bringing 15-years of leadership experience in biotech and pharma
consulting, Dr. Shaw was formerly the Chief Operating Officer of
Nuventra Pharma Sciences, where he co-led the company from
inception into a stable, revenue generating business prior to its
sale in May 2021. Regarding Archimedic, Dr. Shaw notes,
“Archimedic’s demonstrated expertise in all three major segments of
medical device development: design, regulatory affairs, and
commercialization, provides real value to its clients, greatly
improving their chances for successful commercialization of their
products and bringing necessary advances to the medical field.”
Dr. Shaw earned dual Bachelor’s Degrees in Chemistry and Biology
from Duke University, followed by his PhD in Biochemistry and
Biophysics from Washington State University. He went on to an
American Heart Association post-doctoral fellowship at the
University of Pennsylvania. He co-developed Nuventra Pharma
Sciences from a two-person boutique clinical pharmacology
consulting shop into a 125-person full-service drug development
consulting group with $22M in annual revenue.
About Archimedic
Since 2009, Archimedic has been helping companies develop drug
delivery, surgical, diagnostic, and home health medical devices.
Helping medtech innovators transform napkin sketch concepts into
market-ready medical devices, Archimedic’s work is advancing cancer
care, preventing hip fractures, improving outcomes for extremely
premature infants, reducing the cost of life-changing drugs, and
much more. Archimedic helps companies with product development,
quality & regulatory affairs, and commercialization
strategy.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912017707/en/
M. Alexander Shaw, Ph.D. Chief Executive Officer Archimedic,
Inc. +1 610-883-6573 ashaw@archimedic.com
Eric Sugalski Chief Technical Officer Archimedic, Inc. +1
610-455-4255 x 703 esugalski@archimedic.com